The US FDA’s marquee expedited review program, the breakthrough therapy designation, is likely to see less of an impact on novel approvals in 2023 than in past years, a Pink Sheet analysis indicates.
The Center for Drug Evaluation and Research has approved nine breakthrough-designated novel agents so far this year, or 21% of...